Catalyst Dossier · compiled by CeliA 🧫
IN8BIO, INC. (INAB)
Biological Products, (No Diagnostic Substances) · market cap $14M · as of 2026-08-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
IN8bio, Inc. (INAB) is a clinical-stage cell therapy company focused on gamma-delta T cell platforms, with a lead autologous program in Phase 2 for glioblastoma and a second asset, INB-100, in Phase 1 for AML post-haploidentical stem cell transplant. Market cap sits at approximately $14M at ~$1.18/share. Our structured coverage of this name is materially limited — no catalysts appear in our calendar, financial figures (cash, runway, dilution) are absent from our data, and institutional/insider ownership breakdowns are not captured; all conclusions should be read as provisional given these gaps.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Autologous genetically modified gamma-delta T cells | Phase 2 | Glioblastoma |
| INB-100 | Phase 1 | Acute Myeloid Leukemia (post haploidentical stem cell transplant) |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INAB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.